RxDoctor Payments Data

Charlene Thompson

Family · Baton Rouge, LANPI 1174046130

Payments from drug & device makers

$2,379in general payments, 2019–2025

Across 65 payments — averaging $36.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$770
  • AstraZeneca$486
  • Inspire Medical Systems, Inc.$434
  • Boehringer Ingelheim$208
  • Lilly USA, LLC$204
  • Verona Pharma, Inc.$97
  • plus $180 from 4 others

What the payments were for

  • Food & beverage$2,379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,379 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$34,653
Medicare patients
314
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter451$342,505
SucraidSacrosidase13$185,566
Stiolto RespimatTiotropium Br/Olodaterol Hcl97$66,260
Breztri AerosphereBudesonide/Glycopyr/Formoterol87$65,697
NucalaMepolizumab13$47,678
Spiriva RespimatTiotropium Bromide56$38,602
Breo ElliptaFluticasone/Vilanterol50$24,875
Albuterol Sulfate HfaAlbuterol Sulfate443$12,230
Fluticasone-SalmeterolFluticasone Propion/Salmeterol66$11,033
EliquisApixaban14$7,914
Wixela InhubFluticasone Propion/Salmeterol52$6,407
Arnuity ElliptaFluticasone Furoate13$3,269
Ventolin HfaAlbuterol Sulfate44$2,447
Ipratropium Bromide35$949
Montelukast Sodium111$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta$770$418,327527 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$208$104,862153 claims
AstraZenecaBreztri Aerosphere$486$65,69787 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.

Other family in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →